Skip to content

Exercise Dose-Response on Features of the Metabolic Syndrome

Dose-Response Effects of Aerobic Exercise on Insulin Sensitivity and the Metabolic Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00687128
Enrollment
93
Registered
2008-05-30
Start date
2004-10-31
Completion date
2010-04-30
Last updated
2012-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Metabolic Syndrome, Obesity

Keywords

Insulin resistance, Metabolic syndrome, Aerobic exercise, Exercise behavior

Brief summary

This study investigates the degree of improvement in insulin resistance and features of the metabolic syndrome in non-diabetic overweight or obese subjects after training in a low-intensity, moderate-intensity or non-aerobic exercise program, as well as self-initiated exercise behavior after the assigned exercise program.

Detailed description

The proposed study is a randomized, open study comparing low-intensity and moderate-intensity aerobic exercise versus non-aerobic (stretching) exercise on direct measurements of insulin resistance and variables associated with the metabolic syndrome. This 6-month intervention will be followed by an additional 6-month follow-up period during which subjects will be encouraged to maintain their exercise regimen (along with their prescribed diet) but without scheduled supervision. Behavioral variables associated with adherence will be analyzed along with changes in the above physiological variables.

Interventions

BEHAVIORALLow-intensity treadmill exercise

Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.

BEHAVIORALModerate-intensity treadmill exercise

Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.

BEHAVIORALNon-aerobic stretching exercise

Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.

Sponsors

National Center for Research Resources (NCRR)
CollaboratorNIH
Charles Drew University of Medicine and Science
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Males or females, age 18-60 * At least 2 of the 5 components of the NCEP definition of the metabolic syndrome, provided that either the triglyceride or waist circumference criteria are met * Body mass index of 25-45 kg/m2 * Subjects not currently following a regular exercise program nor an optimal diet, and who self-report their activity level as sedentary * Able to understand and sign the informed consent form, follow the instructions given in the study, attend all necessary clinic visits, and undergo all required study procedures

Exclusion criteria

* Past or current diabetes mellitus * Significant concurrent medical illnesses (chronic liver or renal disease, malignancies, recent or chronic infections including HIV, surgeries or other hospitalizations within four weeks prior to screening), uncontrolled hypertension (BP \>160/90 mm Hg), or abnormal TSH on screening. * Conditions that may contraindicate physical activity (clinically significant cardiac, pulmonary, orthopedic, rheumatological or neurological diseases) * Cardiovascular disease not controlled with medical therapy, or invasive vascular procedures within six months prior to screening * Subjects found on resting EKG or stress testing to have underlying cardiac abnormalities * Perimenopausal women who are experiencing irregular menses * Pregnant or lactating women * Subjects who may have limited exercise tolerance because of treatment with β-adrenergic blockade agents, at least until agents of alternate drug classes can be substituted * Subjects with concurrent endocrinopathies * Subjects receiving concurrent treatment with metformin, thiazolidinediones, systemic glucocorticoids, or any weight loss agents * Subjects who expect to require medications during the course of the study that may affect their metabolic profile, including systemic glucocorticoids and hormone replacement therapies * Subjects who cannot complete the stress test due to physical limitations * Any other factors that, in the opinion of the investigators, may interfere with the safe conduct, the successful completion, or the quality of the data obtained from the study

Design outcomes

Primary

MeasureTime frame
Insulin sensitivity (clamp)6 months

Secondary

MeasureTime frame
Body mass index, waist circumference6 and 12 months
Fat mass, fat-free mass, lean body mass (DEXA)6 and 12 months
Blood pressure6 and 12 months
Fasting glucose, hemoglobin A1c, glucose 2 hours post-oral glucose tolerance test, HOMA-IR index6 and 12 months
Aerobic fitness (VO2Max, Anaerobic threshold, endurance time)6 and 12 months
Apolipoprotein B6 and 12 months
Highly-sensitive C-reactive protein6 and 12 months
Exercise behavior questionnaire scores6 and 12 months
Any adverse events6 and 12 months
Fasting lipid profile6 and 12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026